RU2019123695A - Способы, массивы и их применение - Google Patents
Способы, массивы и их применение Download PDFInfo
- Publication number
- RU2019123695A RU2019123695A RU2019123695A RU2019123695A RU2019123695A RU 2019123695 A RU2019123695 A RU 2019123695A RU 2019123695 A RU2019123695 A RU 2019123695A RU 2019123695 A RU2019123695 A RU 2019123695A RU 2019123695 A RU2019123695 A RU 2019123695A
- Authority
- RU
- Russia
- Prior art keywords
- weeks
- biomarkers
- pancreatic cancer
- binding
- paragraphs
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 108
- 239000000090 biomarker Substances 0.000 claims 70
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 42
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 42
- 201000002528 pancreatic cancer Diseases 0.000 claims 42
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 42
- 239000000523 sample Substances 0.000 claims 26
- 239000000126 substance Substances 0.000 claims 22
- 239000000427 antigen Substances 0.000 claims 14
- 102000036639 antigens Human genes 0.000 claims 14
- 108091007433 antigens Proteins 0.000 claims 14
- 239000012634 fragment Substances 0.000 claims 14
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 12
- 238000012360 testing method Methods 0.000 claims 11
- 101000854931 Homo sapiens Visual system homeobox 2 Proteins 0.000 claims 8
- 102100020676 Visual system homeobox 2 Human genes 0.000 claims 8
- 102000004169 proteins and genes Human genes 0.000 claims 8
- 108090000623 proteins and genes Proteins 0.000 claims 8
- 239000011230 binding agent Substances 0.000 claims 7
- 239000003795 chemical substances by application Substances 0.000 claims 7
- 108020004707 nucleic acids Proteins 0.000 claims 7
- 102000039446 nucleic acids Human genes 0.000 claims 7
- 150000007523 nucleic acids Chemical class 0.000 claims 7
- 102100025626 GTP-binding protein GEM Human genes 0.000 claims 6
- 102000004889 Interleukin-6 Human genes 0.000 claims 6
- 108090001005 Interleukin-6 Proteins 0.000 claims 6
- 239000013068 control sample Substances 0.000 claims 6
- 238000003745 diagnosis Methods 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 229940100601 interleukin-6 Drugs 0.000 claims 6
- 108020004414 DNA Proteins 0.000 claims 5
- 108090000978 Interleukin-4 Proteins 0.000 claims 5
- -1 MAGI Proteins 0.000 claims 5
- 102100027637 Plasma protease C1 inhibitor Human genes 0.000 claims 5
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 5
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 5
- 230000004154 complement system Effects 0.000 claims 5
- 210000000496 pancreas Anatomy 0.000 claims 5
- 238000002560 therapeutic procedure Methods 0.000 claims 5
- JPKJQBJPBRLVTM-OSLIGDBKSA-N (2s)-2-amino-n-[(2s,3r)-3-hydroxy-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2r)-1-(1h-indol-3-yl)-3-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxobutan-2-yl]-6-iminohexanamide Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CCCC=N)[C@H](O)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C=O)C1=CC=CC=C1 JPKJQBJPBRLVTM-OSLIGDBKSA-N 0.000 claims 4
- 102100039358 3-hydroxyacyl-CoA dehydrogenase type-2 Human genes 0.000 claims 4
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 claims 4
- 102100033715 Apolipoprotein A-I Human genes 0.000 claims 4
- 102100040051 Aprataxin and PNK-like factor Human genes 0.000 claims 4
- 102100031277 Calcineurin B homologous protein 1 Human genes 0.000 claims 4
- 102100022789 Calcium/calmodulin-dependent protein kinase type IV Human genes 0.000 claims 4
- 241000839426 Chlamydia virus Chp1 Species 0.000 claims 4
- 102000014447 Complement C1q Human genes 0.000 claims 4
- 108010078043 Complement C1q Proteins 0.000 claims 4
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 claims 4
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 claims 4
- 102100024099 Disks large homolog 1 Human genes 0.000 claims 4
- 101001035740 Homo sapiens 3-hydroxyacyl-CoA dehydrogenase type-2 Proteins 0.000 claims 4
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 claims 4
- 101000733802 Homo sapiens Apolipoprotein A-I Proteins 0.000 claims 4
- 101000890463 Homo sapiens Aprataxin and PNK-like factor Proteins 0.000 claims 4
- 101000777252 Homo sapiens Calcineurin B homologous protein 1 Proteins 0.000 claims 4
- 101000974816 Homo sapiens Calcium/calmodulin-dependent protein kinase type IV Proteins 0.000 claims 4
- 101000943802 Homo sapiens Cysteine and histidine-rich domain-containing protein 1 Proteins 0.000 claims 4
- 101001053984 Homo sapiens Disks large homolog 1 Proteins 0.000 claims 4
- 101000951365 Homo sapiens Disks large-associated protein 5 Proteins 0.000 claims 4
- 101000589015 Homo sapiens Myomesin-2 Proteins 0.000 claims 4
- 101001124900 Homo sapiens PR domain zinc finger protein 8 Proteins 0.000 claims 4
- 101000971468 Homo sapiens Protein kinase C zeta type Proteins 0.000 claims 4
- 101000606502 Homo sapiens Protein-tyrosine kinase 6 Proteins 0.000 claims 4
- 101001059443 Homo sapiens Serine/threonine-protein kinase MARK1 Proteins 0.000 claims 4
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims 4
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims 4
- 102100032965 Myomesin-2 Human genes 0.000 claims 4
- 102100029128 PR domain zinc finger protein 8 Human genes 0.000 claims 4
- 102100021538 Protein kinase C zeta type Human genes 0.000 claims 4
- 102100039810 Protein-tyrosine kinase 6 Human genes 0.000 claims 4
- 102100028921 Serine/threonine-protein kinase MARK1 Human genes 0.000 claims 4
- 229960002685 biotin Drugs 0.000 claims 4
- 235000020958 biotin Nutrition 0.000 claims 4
- 239000011616 biotin Substances 0.000 claims 4
- 238000002512 chemotherapy Methods 0.000 claims 4
- 210000002966 serum Anatomy 0.000 claims 4
- 238000001356 surgical procedure Methods 0.000 claims 4
- 208000000668 Chronic Pancreatitis Diseases 0.000 claims 3
- 206010033649 Pancreatitis chronic Diseases 0.000 claims 3
- 210000004369 blood Anatomy 0.000 claims 3
- 239000008280 blood Substances 0.000 claims 3
- 230000002255 enzymatic effect Effects 0.000 claims 3
- 238000005259 measurement Methods 0.000 claims 3
- 108020004999 messenger RNA Proteins 0.000 claims 3
- 238000002493 microarray Methods 0.000 claims 3
- 230000002285 radioactive effect Effects 0.000 claims 3
- 239000000941 radioactive substance Substances 0.000 claims 3
- 201000009030 Carcinoma Diseases 0.000 claims 2
- 238000002965 ELISA Methods 0.000 claims 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 206010070999 Intraductal papillary mucinous neoplasm Diseases 0.000 claims 2
- 238000001574 biopsy Methods 0.000 claims 2
- 238000011342 chemoimmunotherapy Methods 0.000 claims 2
- 239000000975 dye Substances 0.000 claims 2
- 229960002949 fluorouracil Drugs 0.000 claims 2
- 229960005277 gemcitabine Drugs 0.000 claims 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 2
- 238000009396 hybridization Methods 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 238000009169 immunotherapy Methods 0.000 claims 2
- 238000011503 in vivo imaging Methods 0.000 claims 2
- 230000003211 malignant effect Effects 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 claims 2
- 210000002381 plasma Anatomy 0.000 claims 2
- 238000003752 polymerase chain reaction Methods 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 238000012340 reverse transcriptase PCR Methods 0.000 claims 2
- 208000010576 undifferentiated carcinoma Diseases 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 claims 1
- WUAPFZMCVAUBPE-NJFSPNSNSA-N 188Re Chemical compound [188Re] WUAPFZMCVAUBPE-NJFSPNSNSA-N 0.000 claims 1
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 claims 1
- 239000012099 Alexa Fluor family Substances 0.000 claims 1
- QGZKDVFQNNGYKY-OUBTZVSYSA-N Ammonia-15N Chemical compound [15NH3] QGZKDVFQNNGYKY-OUBTZVSYSA-N 0.000 claims 1
- 101001007348 Arachis hypogaea Galactose-binding lectin Proteins 0.000 claims 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims 1
- OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 claims 1
- 102000053602 DNA Human genes 0.000 claims 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 1
- YCKRFDGAMUMZLT-IGMARMGPSA-N Fluorine-19 Chemical compound [19F] YCKRFDGAMUMZLT-IGMARMGPSA-N 0.000 claims 1
- 101710116158 GTP-binding protein GEM Proteins 0.000 claims 1
- 101000950669 Homo sapiens Mitogen-activated protein kinase 9 Proteins 0.000 claims 1
- 101000606537 Homo sapiens Receptor-type tyrosine-protein phosphatase delta Proteins 0.000 claims 1
- 102000003816 Interleukin-13 Human genes 0.000 claims 1
- 108090000176 Interleukin-13 Proteins 0.000 claims 1
- ZCYVEMRRCGMTRW-AHCXROLUSA-N Iodine-123 Chemical compound [123I] ZCYVEMRRCGMTRW-AHCXROLUSA-N 0.000 claims 1
- 102100037809 Mitogen-activated protein kinase 9 Human genes 0.000 claims 1
- 238000000636 Northern blotting Methods 0.000 claims 1
- 206010055006 Pancreatic sarcoma Diseases 0.000 claims 1
- OAICVXFJPJFONN-OUBTZVSYSA-N Phosphorus-32 Chemical compound [32P] OAICVXFJPJFONN-OUBTZVSYSA-N 0.000 claims 1
- 238000011529 RT qPCR Methods 0.000 claims 1
- 102100039666 Receptor-type tyrosine-protein phosphatase delta Human genes 0.000 claims 1
- 108091006626 SLC12A7 Proteins 0.000 claims 1
- 208000003252 Signet Ring Cell Carcinoma Diseases 0.000 claims 1
- 102100034252 Solute carrier family 12 member 7 Human genes 0.000 claims 1
- 238000002105 Southern blotting Methods 0.000 claims 1
- 108010090804 Streptavidin Proteins 0.000 claims 1
- NINIDFKCEFEMDL-AKLPVKDBSA-N Sulfur-35 Chemical compound [35S] NINIDFKCEFEMDL-AKLPVKDBSA-N 0.000 claims 1
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 claims 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 201000008395 adenosquamous carcinoma Diseases 0.000 claims 1
- CMQZRJBJDCVIEY-JEOLMMCMSA-N alpha-L-Fucp-(1->3)-[beta-D-Galp-(1->4)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O[C@@H](O[C@@H]2[C@H]([C@H](O[C@@H]3[C@H](OC(O)[C@H](O)[C@H]3O)CO)O[C@H](CO)[C@@H]2O)O)[C@@H]1NC(C)=O CMQZRJBJDCVIEY-JEOLMMCMSA-N 0.000 claims 1
- NIGUVXFURDGQKZ-UQTBNESHSA-N alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O[C@]3(O[C@H]([C@H](NC(C)=O)[C@@H](O)C3)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O NIGUVXFURDGQKZ-UQTBNESHSA-N 0.000 claims 1
- 238000003491 array Methods 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 238000000376 autoradiography Methods 0.000 claims 1
- 210000000941 bile Anatomy 0.000 claims 1
- 229940098773 bovine serum albumin Drugs 0.000 claims 1
- 239000002299 complementary DNA Substances 0.000 claims 1
- 229910052805 deuterium Inorganic materials 0.000 claims 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 239000007850 fluorescent dye Substances 0.000 claims 1
- 210000004907 gland Anatomy 0.000 claims 1
- 201000005376 hepatoid adenocarcinoma Diseases 0.000 claims 1
- 238000007901 in situ hybridization Methods 0.000 claims 1
- APFVFJFRJDLVQX-AHCXROLUSA-N indium-111 Chemical compound [111In] APFVFJFRJDLVQX-AHCXROLUSA-N 0.000 claims 1
- 229940055742 indium-111 Drugs 0.000 claims 1
- 229940044173 iodine-125 Drugs 0.000 claims 1
- ZCYVEMRRCGMTRW-YPZZEJLDSA-N iodine-125 Chemical compound [125I] ZCYVEMRRCGMTRW-YPZZEJLDSA-N 0.000 claims 1
- 238000002372 labelling Methods 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 210000004080 milk Anatomy 0.000 claims 1
- 239000008267 milk Substances 0.000 claims 1
- 235000013336 milk Nutrition 0.000 claims 1
- 201000010879 mucinous adenocarcinoma Diseases 0.000 claims 1
- 239000002086 nanomaterial Substances 0.000 claims 1
- 239000013642 negative control Substances 0.000 claims 1
- 238000011275 oncology therapy Methods 0.000 claims 1
- 201000010302 ovarian serous cystadenocarcinoma Diseases 0.000 claims 1
- QVGXLLKOCUKJST-OUBTZVSYSA-N oxygen-17 atom Chemical compound [17O] QVGXLLKOCUKJST-OUBTZVSYSA-N 0.000 claims 1
- 201000002526 pancreas sarcoma Diseases 0.000 claims 1
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 claims 1
- 210000004923 pancreatic tissue Anatomy 0.000 claims 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 claims 1
- 239000002953 phosphate buffered saline Substances 0.000 claims 1
- 229940097886 phosphorus 32 Drugs 0.000 claims 1
- 239000013641 positive control Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 238000002271 resection Methods 0.000 claims 1
- WUAPFZMCVAUBPE-IGMARMGPSA-N rhenium-186 Chemical compound [186Re] WUAPFZMCVAUBPE-IGMARMGPSA-N 0.000 claims 1
- 208000005893 serous cystadenoma Diseases 0.000 claims 1
- 201000008123 signet ring cell adenocarcinoma Diseases 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 229940056501 technetium 99m Drugs 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 229910052722 tritium Inorganic materials 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Medical Informatics (AREA)
- Public Health (AREA)
- Data Mining & Analysis (AREA)
- Databases & Information Systems (AREA)
- Epidemiology (AREA)
- Primary Health Care (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1701572.8A GB201701572D0 (en) | 2017-01-31 | 2017-01-31 | Methods, arrays and uses thereof |
| GB1701572.8 | 2017-01-31 | ||
| PCT/EP2018/052423 WO2018141804A1 (en) | 2017-01-31 | 2018-01-31 | Methods, arrays and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2019123695A true RU2019123695A (ru) | 2021-03-02 |
Family
ID=58462729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019123695A RU2019123695A (ru) | 2017-01-31 | 2018-01-31 | Способы, массивы и их применение |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20190382849A1 (enExample) |
| EP (1) | EP3577464A1 (enExample) |
| JP (1) | JP2020507760A (enExample) |
| KR (1) | KR20190109422A (enExample) |
| CN (1) | CN110325860A (enExample) |
| AU (1) | AU2018214180A1 (enExample) |
| BR (1) | BR112019015633A2 (enExample) |
| CA (1) | CA3051968A1 (enExample) |
| GB (1) | GB201701572D0 (enExample) |
| IL (1) | IL268244A (enExample) |
| MX (1) | MX2019008911A (enExample) |
| RU (1) | RU2019123695A (enExample) |
| WO (1) | WO2018141804A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008117067A2 (en) | 2007-03-27 | 2008-10-02 | Carl Arne Krister Borrebaeck | Protein signature/markers for the detection of adenocarcinoma |
| CA3142634A1 (en) * | 2019-07-03 | 2021-01-07 | Crystal Bioscience Inc. | Anti-b7-h3 antibody and methods of use thereof |
| KR102289278B1 (ko) * | 2019-07-09 | 2021-08-13 | 주식회사 베르티스 | 췌장암 진단용 바이오마커 패널 및 그 용도 |
| JP2023507369A (ja) * | 2019-12-20 | 2023-02-22 | メディミューン，エルエルシー | グリピカン３を標的とするキメラ抗原受容体を用いて癌を治療する組成物及び方法 |
| GB202010970D0 (en) | 2020-07-16 | 2020-09-02 | Immunovia Ab | Methods, arrays and uses thereof |
| AU2022244125A1 (en) * | 2021-03-26 | 2023-10-19 | BioNTech SE | Combination therapy with an anti-ca19-9 antibody and folfirinox in the treatment of cancer |
| CN113336851B (zh) * | 2021-06-30 | 2021-12-24 | 徐州医科大学 | 新型全人源抗人b7h3抗体、包含所述抗体的组合物及其应用 |
| CN120177800B (zh) * | 2025-05-23 | 2025-10-10 | 四川大学 | 血液生物标志物cfp在制备急性胰腺炎诊断试剂的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4486530A (en) | 1980-08-04 | 1984-12-04 | Hybritech Incorporated | Immunometric assays using monoclonal antibodies |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US8632983B2 (en) * | 2005-04-15 | 2014-01-21 | Van Andel Research Institute | Biomarkers for pancreatic cancer and diagnostic methods |
| WO2008117067A2 (en) | 2007-03-27 | 2008-10-02 | Carl Arne Krister Borrebaeck | Protein signature/markers for the detection of adenocarcinoma |
| WO2012031374A1 (zh) * | 2010-09-09 | 2012-03-15 | 北京同为时代生物技术有限公司 | 用于诊断上皮源性癌症的血液标志物及其单克隆抗体 |
| GB201103726D0 (en) | 2011-03-04 | 2011-04-20 | Immunovia Ab | Method, array and use thereof |
| GB201206323D0 (en) * | 2012-04-10 | 2012-05-23 | Immunovia Ab | Methods and arrays for use in the same |
| GB201319878D0 (en) * | 2013-11-11 | 2013-12-25 | Immunovia Ab | Method, Array and use thereof |
| GB201516801D0 (en) * | 2015-09-22 | 2015-11-04 | Immunovia Ab | Method, array and use thereof |
-
2017
- 2017-01-31 GB GBGB1701572.8A patent/GB201701572D0/en not_active Ceased
-
2018
- 2018-01-31 CN CN201880009309.3A patent/CN110325860A/zh active Pending
- 2018-01-31 JP JP2019541330A patent/JP2020507760A/ja active Pending
- 2018-01-31 BR BR112019015633-0A patent/BR112019015633A2/pt not_active Application Discontinuation
- 2018-01-31 RU RU2019123695A patent/RU2019123695A/ru not_active Application Discontinuation
- 2018-01-31 MX MX2019008911A patent/MX2019008911A/es unknown
- 2018-01-31 KR KR1020197022175A patent/KR20190109422A/ko not_active Ceased
- 2018-01-31 EP EP18703545.6A patent/EP3577464A1/en not_active Withdrawn
- 2018-01-31 AU AU2018214180A patent/AU2018214180A1/en not_active Abandoned
- 2018-01-31 US US16/479,064 patent/US20190382849A1/en not_active Abandoned
- 2018-01-31 CA CA3051968A patent/CA3051968A1/en not_active Abandoned
- 2018-01-31 WO PCT/EP2018/052423 patent/WO2018141804A1/en not_active Ceased
-
2019
- 2019-07-24 IL IL268244A patent/IL268244A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20190382849A1 (en) | 2019-12-19 |
| BR112019015633A2 (pt) | 2020-03-17 |
| JP2020507760A (ja) | 2020-03-12 |
| KR20190109422A (ko) | 2019-09-25 |
| AU2018214180A1 (en) | 2019-08-08 |
| CA3051968A1 (en) | 2018-08-09 |
| IL268244A (en) | 2019-09-26 |
| GB201701572D0 (en) | 2017-03-15 |
| EP3577464A1 (en) | 2019-12-11 |
| CN110325860A (zh) | 2019-10-11 |
| MX2019008911A (es) | 2019-09-26 |
| WO2018141804A1 (en) | 2018-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2019123695A (ru) | Способы, массивы и их применение | |
| TWI708058B (zh) | 阿茲海默症及其他神經退化性疾病之生物標記及診斷方法 | |
| KR101032607B1 (ko) | 간암 진단용 단백질성 마커 | |
| KR101073875B1 (ko) | 대장암 진단 마커 및 이를 이용한 대장암 진단방법 | |
| RU2018138639A (ru) | Способ, чип и их применение | |
| US20070292869A1 (en) | Compositions and Methods for Analyzing Renal Cancer | |
| KR20160045547A (ko) | 췌장암 진단용 조성물 및 이를 이용한 췌장암 진단방법 | |
| KR102054857B1 (ko) | 질환의 진단용 조성물 | |
| KR20130046457A (ko) | 신규한 대장암 진단용 마커 및 이를 이용한 대장암 진단 키트 | |
| WO2012081007A2 (en) | Methods of diagnosing and treating pancreatic cancer | |
| JP6639408B2 (ja) | デオキシハイプシン・シンターゼ遺伝子を指標として用いる動脈硬化及びがんの検出方法 | |
| KR102547531B1 (ko) | 주요 우울 장애 치료 반응성 평가용 바이오마커 | |
| US20150338412A1 (en) | Composition for diagnosis of lung cancer and diagnosis kit for lung cancer | |
| KR101657051B1 (ko) | 만성폐쇄성폐질환 진단용 마커 조성물 | |
| KR20240009366A (ko) | 초기 알츠하이머병 진단용 바이오마커 및 이의 용도 | |
| EP2772759A1 (en) | Composition for diagnosis of lung cancer | |
| CN113785200B (zh) | 基于过表达tuba1c蛋白的外泌体的标志物组合物 | |
| JP6004369B2 (ja) | 糖尿病合併症マーカーとなり得る新規ｒａｇｅリガンド | |
| KR20170100213A (ko) | 신장암 진단용 조성물과 진단 마커 검출 방법 | |
| US20130225437A1 (en) | Biomarkers of cancer | |
| KR102533728B1 (ko) | 뇌 유래 엑토좀 특이적 마커와 다중 마커군의 발현 패턴을 이용한 비침습성 치매 진단 방법 | |
| JP2022527983A (ja) | Ｔｕｂａ１ｃタンパク質を過発現するエクソソーム基盤の癌の診断又は予後予測用マーカー組成物 | |
| KR101054953B1 (ko) | 간암을 진단 및 치료하기 위한 분자인 ｓｎｘ１４, 그를 포함하는 키트 | |
| KR100899848B1 (ko) | 폐암 진단용 마커 | |
| JP4474551B2 (ja) | 神経膠腫細胞株ｕ２５１の増殖能抑制剤及び浸潤能抑制剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20210201 |